Xeris Biopharma Holdings (XERS) Depreciation & Amortization (CF) (2020 - 2026)

Xeris Biopharma Holdings has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $337000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 6.98% year-over-year to $337000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 9.79% YoY), and the FY2025 full-year result was $1.3 million, up 7.01% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $337000.0, up from $335000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $391000.0 in Q3 2023, with the low at $281000.0 in Q2 2024.
• Historically, Depreciation & Amortization (CF) has averaged $339000.0 across 5 years, with a median of $337000.0 in 2026.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) fell 27.2% — and 2025, when it advanced 15.66%.
• Xeris Biopharma Holdings' Depreciation & Amortization (CF) stood at $366000.0 in 2022, then dropped by 5.46% to $346000.0 in 2023, then slipped by 9.54% to $313000.0 in 2024, then rose by 7.03% to $335000.0 in 2025, then increased by 0.6% to $337000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $337000.0 (Q1 2026), $335000.0 (Q4 2025), and $338000.0 (Q3 2025), per Business Quant data.